Track Grifols, S.A. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Grifols, S.A. GRFS · Stock Open Grifols, S.A. in new tab

7.16 USD
P/E
10.26
EPS
0.69
Yield
0.75%
Safety Score
77
P/B
1.55
ROE
6.13
Beta
1.17
Target Price
10.87 USD
Loading chart...
Key Metrics
Earnings dateJuly 23, 2026
P/E10.26
EPS0.69
Book Value4.56
Price to Book1.55
Debt/Equity123.22
% Insiders0.005%
Growth
Revenue Growth-0.05%
Earnings Growth0.22%
Estimates
Forward P/E4.90
Forward EPS1.44
Target Mean Price10.87
Dividend
Dividend Yield0.75%
Annual dividends0.07 USD
Ex-Div. DateJuly 2, 2026
Payout30.83%
5y avg Yield2.40%

DCF Valuation

Tweak assumptions to recompute fair value for Grifols, S.A. (GRFS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Grifols, S.A. Logo Grifols, S.A. Analysis (GRFS)

Spain Health Care Official Website Stock

Is Grifols, S.A. a good investment? Grifols, S.A. (GRFS) is currently trading at 7.16 USD. Market analysts have a consensus price target of 10.87 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 10.26. This relatively low multiple may signal that Grifols, S.A. is undervalued compared to historical market norms.

Earnings Schedule: Grifols, S.A. is expected to release its next earnings report on July 23, 2026. The market consensus estimate for Forward EPS is 1.44.

For income investors, Grifols, S.A. pays a dividend yield of 0.75%. With a payout ratio of 31%, the dividend appears sustainable.

Investor FAQ

Does Grifols, S.A. pay a dividend?

Yes, it pays an annual dividend of 0.07 USD (0.75% yield).

What asset class is Grifols, S.A.?

Grifols, S.A. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be July 23, 2026. The company currently has a trailing EPS of 0.69.

Company Profile

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Exchange Ticker
NMS (United States) GRFS
Trades
Dividend Yield
0.75%
5y avg 2.40%
Annual Dividends
0.07USD
Next Ex. Div Date
July 2, 2026
Payout Ratio
30.83%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
2026
0.27 USD
Aug. 20, 2026 (estimated) 0.1730
July 9, 2026 0.0945
2025
0.17 USD
Aug. 20, 2025 0.1730
2021
0.46 USD
June 14, 2021 0.4560
2020
0.20 USD
Nov. 9, 2020 0.2010
2019
0.39 USD
Dec. 11, 2019 0.2200
June 18, 2019 0.1740
2018
0.48 USD
Dec. 11, 2018 0.2280
June 12, 2018 0.2510
2017
0.38 USD
Dec. 12, 2017 0.2120
June 8, 2017 0.1630
2016
0.35 USD
Dec. 14, 2016 0.1910
June 15, 2016 0.1590
2015
0.35 USD
Dec. 17, 2015 0.1850
June 15, 2015 0.1675
2014
0.30 USD
Dec. 12, 2014 0.1565
June 13, 2014 0.1435
2013
0.14 USD
June 13, 2013 0.1295
May 29, 2013 0.0065
Upcoming Dividends
Name Payment Date Status Amount
Grifols, S.A. Jul 09, 2026 Upcoming 0.094458 USD
Grifols, S.A. Aug 20, 2025 0.173 USD
Stock Splits
Split Date Split Ratio to 1
July 23, 2012 0.500000
Dec. 11, 2012 1.050000
Jan. 4, 2016 2.000000
Dec. 1, 2011 1.100000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion